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OBJECTIVE — Age at onset of type 1 diabetes inﬂuences the risk of microvascular compli-
cations.However,thelong-termriskofproliferativeretinopathywithinthewidespectrumofage
at onset of type 1 diabetes is less well known.
RESEARCH DESIGN AND METHODS — A sample of 1,117 consecutively recruited
patients was drawn from the FinnDiane Study population (4,800 patients). Type 1 diabetes was
deﬁned as age at onset 40 years, insulin treatment initiated within 1 year, and C-peptide 0.3
nmol/l.Retinopathystatuswasgradedbasedonophthalmicrecordsand/orfundusphotographs.
The risk of proliferative retinopathy was studied in age-at-onset groups 0–4, 5–14, and 15–40
years.
RESULTS — The mean durations to proliferative retinopathy were 24.3 (22.7–25.9) years in
the 0–4 years group, 20.1 (19.2–21.1) years in the 5–14 years group, and 21.6 (19.8–23.3)
years in the 15–40 years group (P  0.001). In a Cox regression model, with A1C, blood
pressure,sex,andBMIascovariates,thehighestriskofproliferativeretinopathywasobservedin
the5–14yearsgroup(hazardratio1.90[95%CI1.45–2.48],P0.001).Diabetesonset0–4vs.
5–14yearsmadenodifferenceinthelong-termriskofproliferativeretinopathy(P0.2).When
splitintotwogroups,ageatonset15yearswasassociatedwithahigherlong-termriskthanage
at onset 15 years (1.82 [1.40–2.36], P  0.001).
CONCLUSIONS — Age at onset signiﬁcantly modiﬁes the long-term risk of proliferative
retinopathy. The highest risk is in age-at-onset group 5–14 years, whereas the lowest risk is in
age-at-onset group 15–40 years.
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P
roliferative retinopathy is a severe
microvascular complication in pa-
tients with type 1 diabetes. After 20
years of diabetes, almost all patients with
type 1 diabetes and 58% of patients with
type2diabetesshowsignsofretinopathy.
When retinopathy worsens, severe visual
loss eventually threatens 5–10% of the
patients (1). The most severe form of ret-
inopathy is proliferative retinopathy, and
most of the patients with this complica-
tion will become blind after 5–10 years
without treatment (2). The prevalence of
proliferative retinopathy varies between
13 and 50% after 15–25 years of diabetes
in patients who need insulin (3,4).
Several risk factors for diabetic reti-
nopathyhavealreadybeenidentiﬁed.The
prevalence of any retinopathy is strongly
related to duration of diabetes and glyce-
mic control (1,4). Poor glycemic control
increases both the incidence and the pro-
gression of retinopathy (5). Male sex and
high blood pressure further increase the
riskofretinopathy(3).Geneticfactorsare
also likely to play a major role (6). It is of
note that the age at onset of diabetes may
modify the metabolic phenotype of the
patients and thus predispose certain pa-
tients to diabetic retinopathy. In particu-
lar, diabetes onset at age 5 years may
have a protective effect on the develop-
ment of retinopathy (7,8). Thus, it can be
hypothesized that because the incidence
of type 1 diabetes is on the rise and the
increase has been greatest in children
aged0–4years(9),theremaypossiblybe
a decrease in the overall risk of retinopa-
thy. The studies so far have not focused
on the onset of type 1 diabetes in adult-
hood, and therefore the number of pa-
tients with late-onset diabetes has been
rathersmallandnotlargeenoughtostudy
the effect of late age at onset on the risk of
proliferative retinopathy. Furthermore, it
is not yet known whether young age at
onset is a protective factor in the long
termorwhetheritonlydelaystheonsetof
proliferative retinopathy. Therefore, the
aimofthisstudywastoelucidatehowthe
age at onset of type 1 diabetes inﬂuences
thelong-termriskofproliferativeretinop-
athy in patients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— The present study is a
retrospective cohort study, undertaken as
part of the ongoing FinnDiane Study
(Finnish Diabetic Nephropathy Study),
which has since 1997 collected compre-
hensive data from patients with type 1 di-
abetes at 92 centers throughout Finland,
including primary care as well as second-
ary and tertiary care hospitals with the
aim of identifying genetic and environ-
mental risk factors for diabetes complica-
tions. All adult patients with type 1
diabetesatthesecentershavebeeninvited
toparticipateintheFinnDianeStudy,and
78% have responded positively (10). The
recruitment strategy is random because
the only inclusion criterion is type 1 dia-
betes, and every patient at the recruiting
centers has been invited. The FinnDiane
Studyhastodaterecruited4,800patients
with type 1 diabetes, and although it is
not by strict deﬁnition a population-
based study, the distribution of the pa-
tients closely follows the distribution of
the general population in Finland. Thus,
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regarding the geographic location or se-
lection of patients in the recruiting cen-
ters. The protocol is in accordance with
the Declaration of Helsinki and was ap-
proved by the ethics committee of the
Helsinki University Central Hospital.
Inclusion of patients in the present
studywasbasedontheascendingorderof
theFinnDianepatientidentiﬁcationnum-
bers. Thus, the consecutively recruited
patients from the very beginning of the
FinnDiane Study were the ﬁrst to be in-
cluded in this study. This approach has
two advantages. First the sampling frame
should be as random as possible with re-
gard to ophthalmic status and the treat-
ment of diabetes and its complications.
Second,thesepatientshadthelongestdu-
ration of type 1 diabetes because they
were the ﬁrst ones to participate in the
FinnDiane study.
We obtained fundus photographs
and/or records of fundus examinations
performed by a specialist in ophthalmol-
ogy for 1,117 consecutively recruited pa-
tients. These patients were required to
have onset of diabetes at the age of 40
years, C-peptide 0.3 nmol/l (11), and
insulin treatment initiated within 1 year
of diagnosis. For 972 of 1,117 (87%) pa-
tients, C-peptide concentrations were
0.033 nmol/l, which represents the de-
tection limit of the assay (Human C-
Peptide RIA Kit, Linco Research., St.
Charles, MO). Records of fundus exami-
nations by a specialist in ophthalmology
were available for 917 of 1,117 (82%) pa-
tients, and fundus photographs were
available for 851 of 1,117 (76%) patients.
The patients who had fundus photo-
graphs available (n  851) had been pho-
tographed a total of 2,792 times, on a
median of 3 (interquartile range [IQR]
1–5) times per patient. Both records and
photographs were available for 651 of
1,117 (58%) patients. All available data
were used to score the severity and pro-
gression of retinopathy, a procedure han-
dled by an ophthalmologist (K.H.)
unaware of the demographic data and the
presence or absence of other complica-
tions. The Early Treatment of Diabetic
Retinopathy Study (ETDRS)-grading
scale was used, for which 10 represents
no retinopathy, 61 represents prolifer-
ative retinopathy, and 81–85 represents
advanced retinopathy (12). The eye with
the more severe retinopathy was used to
represent the overall retinopathy severity
for a particular patient. In this study laser
treatmentalonewasnottakenasevidence
of proliferative retinopathy because se-
vere nonproliferative retinopathy is also
an indication for scatter laser photo-
coagulation.
Data on medication, cardiovascular
status, diabetes complications, hyperten-
sion, and cardiovascular disease were
obtained using a standardized ques-
tionnaire, which was completed by the
patient’s attending physician. Blood pres-
sure was measured twice in the sitting
position using a mercury sphygmoma-
nometer after a rest of at least 10 min.
Mean arterial blood pressure was calcu-
lated according to the formula: meanarte-
rial pressure  diastolic blood pressure 
1⁄3 (systolic blood pressure  diastolic
bloodpressure).Anthropometricdata,such
as height and weight were recorded, and
blood was drawn for the laboratory mea-
surements, including A1C. Data on all-
cause mortality were obtained from a
national registry maintained by the Popula-
tion Register Centre of Finland.
Statistical analysis
Data are presented as means (95% CI) for
continuous, normally distributed vari-
ablesandmedians(IQR)fornonnormally
distributed variables. SEs are given for
mean differences. Kaplan-Meier survival
analysis was used to estimate time with-
out proliferative retinopathy and a Man-
tel-Coxlog-ranktestwasusedtocompare
survival distributions among different
age-at-onset groups. The risk of prolifer-
ative retinopathy within the age-at-onset
groups was estimated with a Cox propor-
tionalhazardsmodel,controllingforclin-
ically signiﬁcant covariates. One-way
ANOVA, adjusted for multiple compari-
sons (Sidak), was used to compare the
meandifferencesofthesegroups.Propor-
tions were compared with a Kruskal-
Wallistest.Apreviouslypublishedmacro
for SAS statistical software (SAS, Cary,
NC) was used to compute the cumulative
incidence of proliferative retinopathy and
cumulative mortality before the develop-
ment of proliferative retinopathy ac-
counting for competing events (13). All
other statistical calculations were per-
formed with SPSS 15.0 (SPSS, Chicago,
IL, USA).
RESULTS— Tables 1 and 2 show the
clinical characteristics of the patients
studied. The male-to-female ratio was
596:521. Mean age at onset of type 1 di-
abeteswas13.7(95%CI13.1–14.1)years
and the mean duration of diabetes was
25.0 (24.4–25.7) years (Table 1). Prolif-
erative retinopathy was found in 367 of
1,117 (33%) patients. The highest pro-
portion of patients with proliferative reti-
nopathy was found in age-at-onset group
0–4 years (47.0% [95% CI 39.5–54.6]),
the second highest in age-at-onset group
5–14 years (38.8% [34.7.5–42.9]), and
the lowest in age-at-onset group 15–40
years (18.9% [15.0–22.7]) (Table 2).
Ophthalmic follow-up data were avail-
able for a median of 10.8 (IQR 5.9–17.4)
Table 1—Clinical characteristics of patients without any retinopathy compared with patients with nonproliferative and proliferative
retinopathy
No retinopathy
Nonproliferative
retinopathy
Proliferative
retinopathy All patients
n 258 492 367 1,117
Duration of diabetes (years) 13.7 (12.6–14.7)* 24.9 (24.1–25.8)* 33.1 (32.2–34.0)* 25.0 (24.4–25.7)
Age at onset (years) 17.2 (16.2–18.3)* 14.0 (13.2–14.8)* 10.6 (9.9–11.3)* 13.7 (13.1–14.1)
A1C (%) 8.1 (7.9–8.3)† 8.5 (8.3–8.6)* 8.7 (8.5–8.8)* 8.4 (8.4–8.5)
Mean arterial pressure (mmHg) 93.7 (92.4–94.9)* 96.6 (95.7–97.5)* 102.3 (101.1–103.5)* 97.8 (97.2–98.5)
BMI (kg/m
2) 24.3 (23.9–24.7) 25.2 (24.9–25.5)* 25.5 (25.1–25.9)* 25.1 (24.8–25.3)
Mortality 5 (1.9)* 19 (3.9)* 75 (20.4)* 99 (8.9)
Dataaremeans(95%CI)orn(%).One-wayANOVA,adjustedformultiplecomparisons(Sidak).DifferencesinproportionswerecomparedwiththeKruskal-Wallis
test. *Signiﬁcant difference between all three groups (P  0.05). †Signiﬁcant difference between two groups.
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retinopathy.
Mean duration from onset of diabetes
to proliferative retinopathy was 21.3
(95% CI 20.6–22.1) years in all patients.
The longest duration to proliferative reti-
nopathy was 24.3 (22.7–25.9) years in the
0–4 years group (n  79), whereas the
shortest was 20.1 (19.2–21.1) years in
the 5–14 years group (n  212). In the
15–40 years group the duration to prolif-
erative retinopathy was 21.6 (19.8–23.3)
years (n  76) (Table 2). The mean  SE
difference in the duration of diabetes to
proliferative retinopathy between age-at-
onsetgroups0–4and5–14yearswassta-
tistically signiﬁcant (4.2  0.9 years, P 
0.001).However,themeandifferencebe-
tween the other two groups did not reach
statistical signiﬁcance. The youngest age-
at-onsetgrouphadthelongestdurationof
diabetes (31.12 [95% CI 29.5–32.7]
years),highestA1C(8.8[8.5–9.0]%),and
thehighestproportionofpatientswithC-
peptide below the detection limit (96.4
[92.4–98.7]%) (Table 2). Patients with
proliferative retinopathy had the highest
mortality (20.4%), the highest BMI (25.5
[25.1–25.9] kg/m
2), and the longest du-
ration of diabetes (33.1 [32.2–34.0]
years) (Table 1).
In the Cox proportional hazards
model, with potentially signiﬁcant risk
factors (A1C, blood pressure, sex, and
BMI) as covariates, onset of diabetes be-
tween 5 and 14 years of age increased the
risk of proliferative retinopathy the most
(hazard ratio [HR] 1.90 [95% CI 1.45–
2.48], P  0.001) as contrasted with age-
at-onset group 15–40 years (Table 3).
Similarly, patients with age at onset 0–4
yearshadahigherriskofproliferativeret-
inopathy (1.61 [1.16–2.23], P  0.002).
Asfortheothercovariates,theriskofpro-
liferative retinopathy increased 15% with
every unit increase in A1C percentage
(1.15 [1.07–1.23], P  0.001) and 3%
with every 1 mmHg increase in mean ar-
terial blood pressure (1.03 [1.02–1.04],
P  0.001). Male sex and BMI did not
inﬂuence the risk of proliferative retinop-
athy.Whenage-at-onsetgroup0–4years
was compared with the age-at-onset
group with the highest risk (5–14 years),
thelong-termriskofproliferativeretinop-
athy, adjusted for the above-mentioned
covariates, showed no difference (0.85
[0.65–1.10],P0.2).Theworstprogno-
sis seems to be in age-at-onset group 5–9
years. However, if compared with age at
onset 10–14 years, this difference did not
reach statistical signiﬁcance (1.29 [0.98–
1.70], P  0.07). Because the patients in
groups5–9and10–14yearsdidnothave
a signiﬁcantly different risk, they are pre-
sented as a combined age-at-onset group
5–14 years in this study.
The Kaplan-Meier survival analysis
stratiﬁed by various age-at-onset groups
illustrates the progression to proliferative
retinopathy (Fig. 1). Median times with-
out proliferative retinopathy were 28.9
(24.6–33.2), 29.2 (26.1–32.2), and 37.8
(32.3–43.4) years in age-at-onset groups
0–4 years, 5–14 years, and 15–40 years,
respectively (P  0.001, Mantel-Cox log-
ranktest)(Fig.1).Despitetheinitialdelay
intheprogressiontoproliferativeretinop-
athy in the youngest age-at-onset group,
the long-term risk between age-at-onset
groups 0–4 and 5–14 years was no dif-
ferent (P  0.224, Mantel-Cox log-rank
test) (Fig. 1). However, there was a signif-
icant difference when the patients were
split into two groups according to age at
onset before or after 15 years of age (P 
0.001,Mantel-Coxlog-ranktest).Median
times without proliferative retinopathy
were 28.9 (95% CI 26.4–31.4) years for
the patients with age at onset before 15
years and 37.8 (95% CI 32.3–43.4) years
for the patients with age at onset after 15
Table 3—Risk of proliferative retinopathy in age-at-onset groups 0–4 years and 5–14 years
compared with age-at-onset group 15–40 years: Cox proportional hazards model
Variable HR (95% CI) P value
Age at onset 15–40 years 1
Age at onset 0–4 years 1.61 (1.16–2.23) 0.004
Age at onset 5–14 years 1.90 (1.45–2.48)  0.001
Male sex 1.07 (0.86–1.33) 0.6
A1C (%) 1.15 (1.07–1.23)  0.001
Mean arterial pressure (mmHg) 1.03 (1.02–1.04)  0.001
BMI 1.02 (0.99–1.05) 0.3
Age-at-onset group 0–4 years, n  164; age-at-onset group 5–14 years, n  537; age-at-onset group 15–40
years, n  400.
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was signiﬁcantly higher in those patients
with age at onset before 15 years versus
after 15 years, when adjusted for the
above-mentioned covariates (HR 1.82
[95% CI 1.40–2.36], P  0.001).
A total of 99 of the 1,117 patients
(8.9%) had died during the follow-up. Of
these 75 of 99 (75.8%) had proliferative
retinopathy (Table 1). The remaining 24
of 99 (24.2%) patients did not have pro-
liferative retinopathy.
CONCLUSIONS — This study shows
that the patients with the youngest age at
onset (0–4 years) have the longest mean
duration of type 1 diabetes without pro-
liferative retinopathy (24.3 [95% CI
22.7–25.9] years). This observation is in
line with earlier ﬁndings regarding dia-
betic retinopathy and nephropathy
(7,8,14). However, the long-term risk of
proliferative retinopathy is no different
between age-at-onset groups 0–4 and
5–14 years despite the initial advantage
for those with earlier onset of diabetes.
Ultimately, the survival curves for these
twogroupscrosseachotherwhenthedu-
ration of diabetes approaches 30 years.
The survival curve for those patients with
age at onset of type 1 diabetes at 15–40
years appears to be consistently better
than that for patients with younger age of
onset.
Good self-care of diabetes correlates
with good metabolic control (15). It can
be hypothesized that it may be easier to
learn good self-care skills at a very young
age compared with the prepubertal pe-
riod (14). Learning good self-care skills
may take a longer time in prepubertal
children compared with young children,
which would explain the delayed onset of
proliferative retinopathy in the youngest
patients.Inadditiontobehavioralfactors,
hormonal changes in puberty may con-
tribute to worse metabolic control (16).
Furthermore, the initial advantage for the
younger patients may be due to more
stringent management of type 1 diabetes,
becausethishasbeenshowntoreducethe
decline in insulin production (17).
Diabetes onset at puberty has been
linked to a less aggressive form of type 1
diabetes (18), and it has also been ob-
served that -cells are better preserved
when type 1 diabetes begins in the adult-
hood (19). We observed a longer time
without proliferative retinopathy as well
as a lower risk of proliferative retinopathy
for age-at-onset group 15–40 years. This
ﬁnding could be explained by preserva-
tion of -cells as these patients also had
the highest C-peptide concentrations.
The Diabetes Control and Complications
Trial data indicated that patients with any
residual C-peptide secretion, but espe-
cially those with the highest stimulated
concentrations, had a reduced incidence
ofretinopathyandnephropathy(20).The
roleofC-peptidehasbeensomewhatcon-
troversial, because it has not been linked
to retinopathy in other studies (3). In our
study those patients with a higher C-
peptide concentration had less prolifera-
tive retinopathy, later age at onset, and
lower A1C (Tables 1 and 2). The associa-
tion of age at onset with the risk of dia-
betic retinopathy may not be limited to
type1diabetes.Ithasrecentlybeennoted
that a higher age at onset of diabetes re-
duces the risk of retinopathy in type 2
diabetic patients as well (21).
An advantage of our study is that the
timing of onset of proliferative retinopa-
thyisrobust,becauseitwasbasedonsev-
eral examinations and/or serial fundus
photographs. Only in 19 of 367 (5.2%)
patientswasproliferativeretinopathydis-
covered at their ﬁrst fundus examination
by an ophthalmologist. Thus, there were
no available reference points for these pa-
tients before they had developed prolifer-
ative retinopathy. Because these 19
patients comprise only 5.2% of all the pa-
tients with proliferative retinopathy, the
possible inaccuracy introduced by these
patients was judged to be negligible, and
they were kept in the study. Importantly,
this decision also kept the original ran-
dom sampling frame intact. All of the
other patients (n  348) had had at least
oneophthalmicexaminationonamedian
of 0.7 (0.3–1.8) years before the diagno-
sis. In addition, records of treatment and
follow-up were available for nearly all
(364 of 367) patients with proliferative
retinopathy. Retinal photography has
been reported to be the most sensitive
screening method for diabetic retinopa-
thy. The sensitivity is in excess of 80% in
detecting proliferative retinopathy (22).
Ophthalmoscopy has less sensitivity but
converselyahigherspeciﬁcity.Itprovides
good results in the hands of trained pro-
fessionals such as ophthalmologists and
diabetologists,especiallywhenusedinre-
peated examinations (22). In Finland, the
national guidelines for the screening of
diabetic retinopathy were published al-
readyin1992andupdatedin2006,along
the European guidelines, which empha-
sizefundusphotographyasthepreferable
screening method (23). As a result, fun-
dus photographs were available for as
many as 851 of 1,117 (76%) patients.
Figure 1—Kaplan-Meier survival analysis of the cumulative proportion of patients without
proliferative retinopathy (PDR) in 1,117 patients stratiﬁed into three groups according to age at
onset (P  0.001, Mantel-Cox log-rank test).
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sults may be limited by the fact that the
FinnDianeStudyisnotbystrictdeﬁnition
a population-based study. In any case, a
possible selection bias is unlikely because
the geographic distribution of the Finn-
Diane patients closely follows the distri-
bution of the general population, and the
patient recruitment at the participating
centers can be considered random. Fur-
thermore, the diagnosis and treatment of
diabetes and its complications are fairly
uniform across Finland. There has been
only one population-based study on the
prevalence of proliferative retinopathy
among patients with type 1 diabetes in
Finlandinasampleof1,067patients,and
the results are comparable to ours (24).
Another potentially important issue is the
competing risk of death. Accounting for
the cumulative mortality by using a pre-
viouslypublishedSASmacro(13)didnot
change the outcome of either Kaplan-
MeierorCoxregressionanalysis.Interest-
ingly, 75 of 99 patients who had died
during the follow-up had developed pro-
liferative retinopathy. The ultimate long-
term risk of proliferative retinopathy
appears therefore to be roughly 75% for
the FinnDiane study population. Finally,
there may also be a confounding cohort
effect in the present study, because the
oldest patients may have a worse progno-
sis than the younger ones attributable to
improvements in medical care of diabetes
(25).However,wetestedthedataforsuch
a cohort effect in two ways. The ﬁrst way
was to use the year of onset of diabetes as
a continuous variable in the Cox regres-
sion model. The other was to use the de-
cade of onset of diabetes as a categorical
variable. Both of these variables were sta-
tistically nonsigniﬁcant.
In summary, our study shows a
longer time free of proliferative retinopa-
thy in the youngest patients. It appears
that this initial advantage gradually wears
off in the long term. In contrast, those
patients with age at onset of type 1 diabe-
tes between 15 and 40 years may have a
consistentlybetterprognosisthananypa-
tient group with age at onset 15 years.
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